Based on the Neoleukin Therapeutics, Inc stock forecast from 0 analysts, the average analyst target price for Neoleukin Therapeutics, Inc is not available over the next 12 months. Neoleukin Therapeutics, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Neoleukin Therapeutics, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Neoleukin Therapeutics, Inc’s stock price was USD 4.03. Neoleukin Therapeutics, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.
No recent analyst target price found for Neoleukin Therapeutics, Inc
No recent average analyst rating found for Neoleukin Therapeutics, Inc
Company Overview
Aquinox Pharmaceuticals, Inc., a pharmaceutical company, engages in discovering and developing therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Read Less
Aquinox Pharmaceuticals, Inc., a pharmaceutical company, engages in discovering and developing therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aq...Read More
Stock Target Advisor's fundamental analysis for Neoleukin Therapeutics, Inc's stock is Very Bearish.
Unfortunately we do not have enough data on AQXP's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AQXP's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AQXP's stock to indicate if its overvalued.
The last closing price of AQXP's stock was USD 4.03.
The most recent market capitalization for AQXP is USD 0.10B.
Unfortunately we do not have enough analyst data on AQXP's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AQXP !
Please login to proceed
Sorry - extended search is only available for registered users.
